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Objective: This study was performed to confirm the feasibility of cryopreserved tra-
cheal allotransplantation in primates, the anatomy and immunology of which are
considered to be more closely related to those of humans than those of other animals.
Methods: Cryopreserved tracheal allotransplantations were performed in 3 recipient
primates. In the control group fresh tracheal allotransplantations were performed in
2 primates (control A), and a tracheal allotransplantation with a simply frozen tra-
cheal graft was performed in 1 primate (control B). Monthly bronchoscopic exam-
inations, histologic examinations, electron microscopic examinations, and
immunohistochemical investigations were performed in each of the primates.
Results: In the cryopreserved tracheal allotransplantation group, 3 recipient monkeys
were killed on the 35th, 144th, and 387th postoperative days, respectively. All grafts
were incorporated by the recipient trachea without stenosis in the cryopreserved
group. In the control group 2 recipient monkeys were killed on the 93rd postopera-
tive day (control A), and one was killed on the 84th postoperative day (control B).
Severe stenosis was observed after the transplantation in all of the control monkeys.
Immunologic reactions appeared to be attenuated by the cryopreservation, whereas
T cell–mediated immunologic rejection (control A) and loss of cartilage viability
(control B) were considered to be the causes of graft failure in the control group.
Conclusion: The immunogenicity of the tracheal allografts was reduced by cryo-
preservation, and cryopreserved tracheal allotransplantation was successful in our
primate model. Further investigation of cryopreserved tracheal allotransplantation
with regard to proper clinical applications and the limitations of the procedure
should be performed.
Although the possible clinical application of cryopreserved trachealallotransplantation has been investigated in various animal mod-els, such as dogs and rats, with encouraging results,1-5 there is stillsome concern regarding interspecies differences in immunoreac-tions, tissue remodeling, anatomy, and so on. Moreover, the his-tory of cryopreserved cardiac valve allotransplantation suggests
that immunologic rejection is inevitable.6 Improvements in tissue cryopreservation
techniques have made it possible to supply cryopreserved tissues when there is a
clinical demand for them,7 and many experiments have shown that the immunore-
activity of cryopreserved tracheal allografts is less potent than that of fresh allo-
grafts.4,5,8 Although some researchers have commented that the clinical
applications of cryopreserved tracheal allotransplantations might be limited,9-13 the
potential usefulness of cryopreserved tracheal allografts in critical situations, such
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as congenital long-segment tracheal stenosis, should be
fully investigated. Cryopreserved tracheal allografts may be
applied in critical situations, such as tracheal stenosis, as
has been shown by Jacobs and colleagues14 and Elliot and
coworkers15 using chemically preserved allografts and by
Kunachak and colleagues using irradiated cryopreserved
allografts.16
This study was designed to examine the feasibility of
using cryopreserved tracheal allografts in clinical applica-
tions. Primates were selected as our animal model of choice
from the viewpoint of anatomy and the close immunologic
relationship between primates and human beings.
Materials and Methods
Humane Animal Care
Special humane animal-care measures were taken in compliance
with the “Guide for Animal Experimentation, Faculty of
Medicine, University of Tokyo, revised 1996” and the “Guide for
the Care and Use of Laboratory Animals” prepared by the Institute
of Laboratory Animal Resources and published by the National
Institute of Health (National Institutes of Health publication No.
85-23, revised 1985). The number of animals was limited to the
minimum number necessary to obtain useful results.
Preparation of Cryopreserved Tracheal Allografts
After killing the donor primates (Japanese monkey: Macaca fus-
cata), the tracheas were dissected under sterile conditions. After
immersing the tracheas in Roswell Park Memorial Institute
(RPMI) medium 1640 (#31800-022; Gibco BRL, Life
Technologies, Inc) containing 15% fetal bovine serum (#26140-
079, Gibco BRL) and 4 kinds of antibiotics (cefmetazole sodium,
240 µg/mL; lincomycin hydrochloride, 120 µg/mL; vancomycin
hydrochloride, 50 µg/mL; and polymixin B sulfate, 1000 U/mL)
for 24 hours at 4°C, the tracheas were conjugated in RPMI
medium 1640 containing 20% fetal bovine serum and 10%
dimethylsulfoxide (#134-06, Nacalai Tesque Inc) and then frozen
in a programmable freezer (Profreezer, NipponFreezer Co). The
following freezing program was used: the specimens were cooled
from room temperature to 4°C at a rate of 3°C/min and then main-
tained at 4°C for 5 minutes. They were then cooled at 1°C/min
from 4°C to –50°C and at 5°C/min from –50°C to –80°C. After the
temperature of the specimens reached –80°C, they were preserved
at –180°C in the vapor phase of liquid nitrogen for 9 to 12 months.
The grafts were thawed rapidly to 37°C and immersed in RPMI
medium 1640 containing 15% fetal bovine serum before trans-
plantation (Figure 1, A). A histologic evaluation of fresh and cry-
opreserved tracheas was performed afterward.
Operative Procedure
Recipient primates (Japanese monkey: Macaca fuscata) were
anesthetized with ketamine and sodium pentobarbital intramuscu-
larly. The primates were intubated orally with a 5-mm endotra-
cheal tube and ventilated with a MARK7 ventilator (Bird Corp).
All animals were placed in a supine position. A median ster-
notomy and a median cervical incision were made, and the cervi-
cal and upper mediastinal tracheas were exposed without
impairing the vessels around the trachea. A 5-ring length of recip-
ient trachea was resected, leaving the membranous portion of the
trachea intact (Figure 1, B). The tip of the endotracheal tube was
placed distal to the distal cut end of the recipient trachea, and ven-
tilation was maintained throughout the procedure. After rapid
thawing of the cryopreserved donor trachea, the membranous por-
tion of the donor trachea was resected (Figure 1, C). A 7-ring
Figure 1. Preparations of cryopreserved tracheal allografts and operative procedure. A cryopreserved tracheal allograft
was prepared (A). Five rings of the recipient trachea were resected with the membranous portion of the graft left intact (B),
and a cryopreserved tracheal allograft was transplanted after the resection of the membranous portion (C). The donor tra-





Murakawa et al General Thoracic Surgery


















length of the donor trachea was then transplanted by means of con-
tinuous suturing with 5-0 PDS II (Z863E; Ethicon, Johnson &
Johnson Int, Brussels, Belgium), and the recipient airway was
reconstructed without impairing the patency of the airway (Figure
1, D). The first and last rings of the proximal and distal end of the
donor trachea were used as suturing cuffs. Thus the 5-ring length
of recipient trachea was reconstructed with a cryopreserved allo-
graft. A pedicled omental flap was not used. After full recovery
from anesthesia, the recipient monkeys were extubated and trans-
ferred to a recovery room. Careful postoperative care, especially
with regard to airway clearance, was taken. A prophylactic daily
intramuscular injection of 1 g of ampicillin was performed until
the seventh postoperative day to prevent postoperative mediastini-
tis. No immunosuppressants were given at any time during the
course of the experiment. Cryopreserved tracheal allotransplanta-
tions were performed in 3 monkeys.
Study Control
Several experiments have shown that cryopreservation attenuates
the allogenicity of tracheal allografts,4,5,8 and cryopreservation
with a programmable freezer is believed to increase the tissue via-
bility of cryopreserved allografts.7 To confirm whether these find-
ings are applicable in primates, we performed fresh tracheal
allotransplantations in 2 recipient monkeys immediately after the
removal of the tracheas from the donor monkeys (control A). We
also performed a simple frozen tracheal allotransplantation in 1
recipient monkey with a donor trachea that was conjugated in
RPMI medium 1640 without dimethylsulfoxide and immediately
frozen in liquid nitrogen without using a programmable freezer
(control B). The operative procedure for the study control groups
was the same as that for the programmed-frozen tracheal allo-
transplantations.
Postoperative Evaluations
Monthly flexible fiberoptic bronchoscopies were performed after
the tracheal allotransplantations to observe changes within the tra-
chea. During chronic periods, the recipient monkeys were killed,
and the transplanted grafts were removed en bloc for pathologic
examination. Histologic changes in the allotransplanted tracheas
were examined with hematoxylin-and-eosin staining, immunohis-
tochemical staining, scanning electron microscopy, and transmis-
sion electron microscopy. Histologic changes in the tracheas
during the preparation of the tracheas were also examined.
Immunostaining reactions for CD3, major histocompatibility
complex (MHC) class II antigen, and S100 protein were detected
with the DAKO catalyzed signal amplification system (K1500,
DAKO) for each 5-µm section. The primary antibodies were anti-
CD3 antibody (A0452, DAKO A/S) diluted 1:50, anti-MHC class
II antibody (M0775, DAKO A/S) diluted 1:50, and anti-S100 pro-
tein antibody (Z0311, DAKO A/S) diluted 1:1000.
Figure 2. Histologic and electron microscopic findings after graft thawing. After the cryopreservation and thawing proce-
dure, the major histologic change was the detachment of the airway epithelium (A and B). The intracellular organelles in
the residual epithelium were mostly destroyed (C). The cartilage was well preserved, even after 12 months of cryopreser-
vation (A). A, Hematoxylin-and-eosin staining, original magnification ×10; B, scanning electron microscopy, original mag-
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The most remarkable change produced by the cryopreserva-
tion and thawing procedure was the exfoliation of airway
epithelial cells in the tracheal allograft (Figure 2, A and B).
After the detachment of the airway epithelium, the basal
membrane directly exposed the luminal surface of the graft
(Figure 2, A and B), and the intracellular organelles of the
residual epithelium were mostly destroyed (Figure 2, C). The
structure of the cartilaginous rings was well preserved during
the cryopreservation and thawing procedure (Figure 2, A).
In the cryopreserved tracheal allotransplantation group
(Table 1), all the primates survived the procedure. Although
bronchoscopic examination during the early postoperative
period revealed mucosa sloughing of the transplanted graft
and slight sputum retention, probably caused by the loss of
the tracheal epithelium during the cryopreservation and
thawing procedure, these findings disappeared within 1
month. Recovery was uneventful, with complete patency of
the transplanted allografts (Figure 3, A and B). A small
degree of intercartilaginous tissue shrinkage was observed
TABLE 1. Results for the cryopreserved tracheal allotransplantation group
No. Recipient Donor Preservation period (d) Status of graft Survival (d) Cause of death
1* 7.0 kg, male 8.0 kg, male 367 Incorporated 35 Killed
2* 8.6 kg, male 7.6 kg, female 282 Incorporated 144 Killed
3* 7.6 kg, female 8.0 kg, male 302 Incorporated 387 Killed
*Donor tracheas were frozen in a programmable freezer and preserved in liquid nitrogen for 9 to 12 months.
Figure 3. Bronchoscopic, macroscopic, and histologic findings of the cryopreserved tracheal allotransplantation group.
Bronchoscopic findings in the cryopreserved tracheal allotransplantation group revealed that grafts were well incorporated,
with good airway patency and a good airway epithelium lining (A). Macroscopic and histologic examination of the trans-
planted grafts in the cryopreserved allotransplantation group revealed a good patency of the implanted grafts with dense
epithelial lining and well-maintained cartilaginous viability (B-E). A small degree of intercartilaginous tissue shrinkage was
observed (C), and a mild degree of mononuclear cell infiltration was observed in the submucosal layer (E). This Figure rep-
resents findings 12 months after transplantation. Hematoxylin-and-eosin staining: C and D, originally ×4; E, originally ×10.
A B
C D E
TABLE 2. Results for the control group
No. Recipient Donor Preservation period (d) Status of graft Survival (d) Cause of death
4* 11.2 kg, male 9.0 kg, male — Severe stenosis 93 Killed
5* 9.0 kg, male 11.2 kg, male — Severe stenosis 93 Killed
6* 5.5 kg, female 8.3 kg, male 36 Severe stenosis 84 Killed
*Fresh tracheal allotransplantations were performed in monkeys 4 and 5, and a simply frozen trachea was allotransplanted in monkey 6.
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(Figure 3, C), but the structure of the cartilaginous rings was
well preserved, even after 12 months. Good epithelialization
of the airway was observed (Figures 3, D and E, and 4, A).
The intracellular organelles of the epithelium appeared to be
well developed, indicating proper functioning (Figure 4, B).
A small degree of mononuclear cell infiltration was
observed in the subepithelial layer (Figure 3, E). In all pri-
mates in this group, these findings were the same, and no
progressive graft failure was observed, even after 12 months.
All the primates in the control group survived (Table 2),
but severe stenosis of the transplanted graft was observed in
all animals (Figure 5, A and B). Slight tracheal narrowing
Figure 4. Electron microscopic findings of the cryopreserved tracheal allotransplantation group. Electron microscopic exam-
ination revealed a dense covering of airway epithelial cells on the implanted grafts (A) and well-developed intracellular
organelles, indicating good cellular function (B). This Figure represents findings 12 months after transplantation. A, Scanning
electron microscopy; original magnification ×2400; B, transmission electron microscopy, original magnification ×6000.
A
B
Figure 5. Bronchoscopic, macroscopic, and histologic findings of the control group. In the control group severe stenosis
occurred in all animals (A and B). Histologically, remarkable cellular infiltration in the transplanted grafts of the fresh allo-
transplantation animals (C) and severe fibrosis and the destruction of the cartilaginous rings in the transplanted graft of the
simply frozen allograft animal (D) were observed. This Figure represents findings 3 months after transplantation.
Hematoxylin-and-eosin staining: original magnifications ×4 (C and D).
A B
C D
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was observed 1 month after the operation, but a 5-mm bron-
choscope could pass through the narrowing portion at this
period. The degree of tracheal narrowing became severe
within 2 months after the operation, and a 5-mm broncho-
scope could not pass through the narrowing portion during
this period. Histologically, remarkable lymphocytic and
mononuclear cell infiltration and malgranulation were
observed in the transplanted grafts of the fresh allotransplan-
tation group (Figure 5, C). Severe fibrosis and the destruction
of the cartilaginous rings were observed in the animal that
received the simply frozen allograft (Figure 5, D).
Results of immunohistochemical staining are shown in
Table 3. Fresh tracheal tissues were negative for CD3 and
S100 protein immunostaining, but the presence of MHC
class II antigen was identified in the airway epithelium of
the fresh trachea. The cryopreserved tracheal allograft tis-
sues were negative for CD3, MHC class II antigen, and
S100 protein. In the cryopreserved tracheal allotransplanta-
tion group, a small degree of mononuclear cell infiltration
was observed in the subepithelial layer (Figure 3, E), but
these infiltrating cells were negative for CD3, MHC class II
antigen, and S100 protein. In the cryopreserved tracheal
allotransplantation group, the epithelial lining on the lumi-
nal surface of the allografts was negative for MHC class II
antigen. In the fresh allotransplantation group, the expres-
sion of MHC class II antigen was identified in the epithe-
lium of the allograft, and the submucosal infiltrating cells
were strongly positive for CD3, MHC class II antigen, and
S100 protein, indicating a positive immunologic reaction.
Discussion
Cryopreserved tracheal allotransplantation has been per-
formed in various animal models, with encouraging results
for clinical applications in human subjects.1-5 The problems
of maintaining blood supply to the transplanted tracheal tis-
sue,11-13,17 trachea allogenicity,18-23 and inevitable infec-
tions have been focused on in animal trials. In animal
experiments cryopreserved tracheal allografts have been
reported to be less immunogenic than fresh allografts,4,5,8,24
and infection of the transplanted trachea or mediastinitis
has been well controlled with antibiotics. As Rose and col-
leagues,25 who performed a tracheal allotransplantation in a
human patient, reported in 1979, the ischemic nature of the
trachea is the most important matter of concern in tracheal
allotransplantation. In animal trials on cryopreserved tra-
cheal allotransplantation, many procedures for improving
the blood supply to the trachea, such as the use of a pedi-
cled omental flap, have been investigated.5 By applying
these methods of improving the blood supply to the graft,
the allotransplantation of a 5-ring length of cryopreserved
trachea without the use of immunosuppressants has became
possible in animal models.11-13
As described in the introduction, interspecies differences
must be examined before cryopreserved tracheal allotrans-
plantations can be safely and successfully performed in
human subjects. Preservation of the blood supply to the
transplanted trachea is essential for successful transplants,
and graft ischemia11-13 and graft rejection4,5,8 are the main
reasons for tracheal transplantation failures. As Salassa and
colleagues26 pointed out, the description of the tracheal
microscopic blood supply in mammals by Sobin and
coworkers27 does not apply in human subjects. Sobin and
coworkers studied microcirculation in the tracheal mucosa
of rabbits, dogs, rats, and guinea pigs and described marked
interspecies differences in the vascular bed. Salassa and col-
leagues26 reported that the fine but important longitudinal
anastomoses along the lateral tracheal wall and transverse
vessels of the trachea were better developed in cats and
dogs than in humans. Moreover, the speed of tissue regen-
eration in dogs is known to be faster than that in humans, as
shown by the history of arterial prosthesis development.28
Most cryopreserved tracheal allotransplantation experi-
ments have been performed with canine models.1,4,5,8 The
results obtained in canine models might be modified by
interspecies differences in blood supply to the trachea.
Consequently, the results of cryopreserved tracheal allo-
transplantation experiments might be more limited than
anticipated on the basis of animal models.26,27
Because tracheal tissue is especially vulnerable to
ischemia, the use of cryopreserved tracheal tissue allotrans-
plantations may be restricted.9-13 Moreover, the additional
problems of rejection and contamination during tracheal
reconstruction are also a concern. Thus far, many experi-
mental models have shown that cryopreserved tracheal allo-
grafts have a lower immunogenicity than that of fresh
allografts and that infectious problems arising from tracheal
TABLE 3. Results for immunohistochemical staining of
tracheal tissues with anti-CD3 antibody, anti-MHC class II
antibody, and anti-S100 protein antibody
MHC S100
CD3 class II protein
Fresh trachea
Airway epithelium – + –
Cells in the subepithelial layer – – –
Cryopreserved trachea
Airway epithelium – – –
Cells in the subepithelial layer – – –
Trachea of the cryopreserved allotransplantation group
Airway epithelium – – –
Infiltrating cells in the subepithelial layer – – –
Trachea of the fresh allotransplantation group
Airway epithelium – + –
Infiltrating cells in the subepithelial layer + + +
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reconstruction do not occur when cryopreserved tracheal
allografts are used.4,5,8,24 One important question that ani-
mal studies have yet to answer is whether cryopreserved tra-
cheal allotransplantations are really possible in human
subjects. This study with primates was performed in an
attempt to answer this question. Most of the findings
obtained in previous animal studies were confirmed in our
study with primates. Cryopreserved allografts have a lower
allogenicity than fresh allografts, partly because of the
exfoliation of airway epithelium, which can act as alloanti-
gen-presenting cells.18,20,22 The importance of programmed
freezing (which augments tissue viability after cryopreser-
vation), good airway epithelialization after tracheal allo-
transplantation, and good tracheal luminal patency without
stenosis or the formation of malgranulation after allotrans-
plantation were also confirmed. The long cryopreservation
period did not influence the ability for a graft to take, and
this result seems to support the previous report by Kushibe
and colleagues.29 The most important result of our study
was the fact that the cryopreserved tracheal allograftings
were successful in the primates. Because improvements in
tissue cryopreservation techniques have made it possible for
a supply of tissues to be created,7 our successful results with
primates, which are similar to humans in both anatomy and
immunology, are encouraging for the clinical use of cryo-
preserved tracheal allografts.
In this study monthly flexible fiberoptic bronchoscopies
were performed after the tracheal allotransplantation as
postoperative evaluation of transplanted graft status, but
biopsies were not performed because we were concerned
about possible impairment of mucosa regeneration by biop-
sies. Instead, the date of animal death in the cryopreserved
allotransplantation group was scheduled at various postop-
erative times (ie, short-term to long-term), as shown in
Table 1, and we evaluated pathology of the transplanted
grafts. Considering the pathologic findings, epithelial
regeneration and mononuclear cell infiltration in the cryo-
preserved allotransplantation group seemed to occur within
1 month. Because slight tracheal stenosis was observed 1
month after the operation in the fresh allotransplantation
group, infiltration of CD3-, MHC class II antigen–, and
S100-positive cells was considered to occur within 1 month.
In this study cryopreserved allografts showed a lower
allogenicity than fresh allografts; however, a small degree
of mononuclear cell infiltration, indicating immunogenic
rejection, was observed even in the cryopreserved allotrans-
plantation group. High allogenicity of fresh tracheal allo-
graft with resultant strong rejection4,22 seems to be
attenuated by a short course of immunosuppressive therapy,
as reported by Kawahara and colleagues.30 In cryopre-
served tracheal allotransplantation, a short course of
immunosuppressive therapy also might be beneficial for
control of rejection.
Of course, our results were obtained with only a small
number of animals. Histologic findings indicating slight
immunogenic rejection, such as mononuclear cell infiltra-
tion, were observed in the cryopreserved tracheal allografts.
Longer follow-up might be necessary to confirm the long-
term fate of transplanted grafts. Moreover, tracheal tissue is
vulnerable to ischemia, and successful tracheal allotrans-
plantations seem to require tracheal organ transplantation,
as pointed out in previous reports.9,10 However, in cases in
which a small augmentation of the tracheal lumen can ben-
efit patients with severe tracheal stenosis, cryopreserved
tracheal homograft allotransplantations may be an impor-
tant contribution to the patient’s respiratory condition.
Jacobs and colleagues14 and Elliot and coworkers15 have
reported the successful management of long-segment tra-
cheal stenosis using chemically preserved tracheal allo-
grafts, and Kunachak and colleagues16 have reported a
successful short-segment laryngotracheal reconstruction
using a cryopreserved tracheal allograft. Their reports
showed that long-segment14,15 and short-segment16 patch
trachoplasty with a tracheal allograft could be applicable
and beneficial for selected patients. In our preliminary
study we tried short-segment reconstruction, using their
method with encouraging results. Short-segment tracheal
reconstruction using our method seems to be applicable for
human subjects. However, there may be a limit to the length
of reconstruction, as shown by previous studies.11-13 In our
future studies long-segment reconstruction with our method
should be tried because most short segments can be primar-
ily reconstructed. Further investigation of the possible clin-
ical applications of cryopreserved tracheal allografts in
human subjects will be important in the future.
Conclusion
Experimental cryopreserved tracheal allotransplantation
was successful in a primate model. Possible clinical appli-
cations of cryopreserved tracheal allografts in human sub-
jects and the limitations of cryopreserved tracheal
allografting should be investigated in the future.
We thank Mr Nobutaka Furuya, Mr Takashi Kubota, and Ms
Noriko Yoneda for their assistance with this experiment.
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